Search

We describe the case of an 18-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) over a period of 10 years. She had suffered predominantly from very painful recurrent swelling of her cheeks. Various therapeutic regimens including nonsteroidal antiinflammatory drugs and steroids had shown only a partial or temporary response. Because tumor necrosis factor-[alpha]-blocking agents have been successfully applied in Crohn's-associated CRMO and the related SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, tumor necrosis factor-[alpha]-blocking therapy with infliximab was initiated. Thereafter, apart from 1 mild episode, no additional recurrences were observed during 21 months of follow-up. Infliximab was well tolerated, and steroids were tapered off. Our observation indicates that infliximab may be an effective therapeutic option in CRMO. Pediatrics 2005;116: 1231-1233; chronic recurrent multifocal osteomyelitis, CRMO, tumor necrosis factor-[alpha] blockage, infliximab. ABBREVIATIONS. CRMO, chronic recurrent multifocal osteomyelitis; TNF-[alpha], tumor necrosis factor-[alpha]; NSAID, nonsteroidal antiinflammatory drug; SAPHO, synovitis, acne, pustulosis, hyperostosis and osteitis., Because the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO) is unknown, a causal therapy is not available. We report our experience with tumor necrosis factor-[alpha] (TNF-[alpha]) blockage in a patient [...]

We describe the case of an 18-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) over a period of 10 years. She had suffered predominantly from very painful recurrent swelling of her cheeks. Various therapeutic regimens including nonsteroidal antiinflammatory drugs and steroids had shown only a partial or temporary response. Because tumor necrosis factor-α-blocking agents have been successfully applied in Crohn's-associated CRMO and the related SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, tumor necrosis factor-α-blocking therapy with infliximab was initiated. Thereafter, apart from 1 mild episode, no additional recurrences were observed during 21 months of follow-up. Infliximab was well tolerated, and steroids were tapered off. Our observation indicates that infliximab may be an effective therapeutic option in CRMO. [ABSTRACT FROM AUTHOR]